Cargando…
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
In the present study we demonstrate that Aza-dC in combination with Amsacrine has major antileukaemic properties in patients who have not already received extensive Ara-C therapy. Eight out of 11 patients in their first relapse of acute leukaemia achieved complete remission. Cross resistance between...
Autores principales: | Richel, D. J., Colly, L. P., Kluin-Nelemans, J. C., Willemze, R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977302/ https://www.ncbi.nlm.nih.gov/pubmed/1713050 |
Ejemplares similares
-
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
por: Richel, D. J., et al.
Publicado: (1988) -
5-Aza-2′-Deoxycytidine (5-Aza-dC, Decitabine) Inhibits Collagen Type I and III Expression in TGF-β1-Treated Equine Endometrial Fibroblasts
por: Alpoim-Moreira, Joana, et al.
Publicado: (2023) -
Effect of Sulforaphane and 5-Aza-2’-Deoxycytidine on Melanoma Cell Growth
por: Chiang, Tung-chin, et al.
Publicado: (2019) -
5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer
por: Patra, Aditi, et al.
Publicado: (2011) -
Epigenetic regulation of the circadian clock: role of 5-aza-2′-deoxycytidine
por: Tomita, Tatsunosuke, et al.
Publicado: (2017)